The company manufactures and trades healthcare products, including pharmaceuticals and food ingredients, while also offering healthcare consultancy and manpower services.
The company lacks a durable competitive advantage, as evidenced by very low average ROCE (4.6%) and ROE (2.5%), which are significantly below the cost of capital. While it claims a transition into integrated healthcare, the financials reflect a low-margin commodity trading profile with no evidence of brand power or switching costs.
Management recently raised 50 million INR via a rights issue but immediately deviated from the stated objectives by using 30 million INR for a 10-year lease from a related party. This suggests capital is being used to support promoter-linked entities rather than high-return organic growth.
The capital loss occurred as the company's transition from commodity trading to integrated healthcare proved to be a facade for siphoning shareholder funds. The 30 million INR related-party lease, funded by the rights issue, failed to generate any incremental return, while the lack of internal audit controls allowed for further undisclosed value leakage. As the revolving door of CFOs continued, the market finally realized the business was merely a low-margin shell for promoter interests, leading to a total collapse in the speculative premium.
RichFakir rates Apollo Ingredients Ltd's business quality as poor — 34/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Apollo Ingredients Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Apollo Ingredients Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Apollo Ingredients Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →